secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2023-11-17T23:59:59+00:00
Accession:  0001628280-23-039394
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience reports FY2023 revenue $245.1M (+20% YoY), net loss $3.60/sh; FY2024 guide $285-290M
--------------------------------------------------------------------------------

- FY2023 revenue $245.1M, up 20% from $203.6M; orders $264M, up 17% from $226.4M.
- FY2023 net loss attributable to common stockholders $204.6M ($3.60 per share), down from $217.9M ($4.04) prior year.
- Q4 revenue $66.9M, up 17% YoY from $57.3M; Q4 net loss $46.2M ($0.81 per share).
- Guidance: FY2024 revenue expected $285M-$290M, reflecting growth.
- Recent highlights: signed Bayer antibody deal worth up to $188M milestones; launched Twist Express Genes with 5-7 day turnaround.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/0001628280-23-039394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/twist-20231117.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-039394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer